Gastrointestinal Complications in Heart Transplant Patients: MITOS Study

Fulminant Hepatic Failure due to Varicella Zoster in a Heart Transplant Patient: Successful Liver Transplant

“…Gastrointestinal complications are common in solid organ transplant recipients, frequent causes include immunosuppressive treatment 5,6 and opportunistic infections. Gastrointestinal symptoms of primary VZV infection in adults may precede cutaneous lesions by 24 to 96 hours, exemplifying the hampering of diagnosis by atypical presentation.…”

Proton Pump Inhibitors Reduce Mycophenolate Exposure in Heart Transplant Recipients-A Prospective Case-Controlled Study

“…heart transplant recipients reported that almost 40% of all patients suffered from gastrointestinal complications of which 86.3% were treated with gastrointestinal-protective comedication (7). Recently, a negative influence of proton pump inhibitor comedication on the MPA-AUC in renal transplant recipients has been published by Miura et al (8).…”

The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients

“…In 1,788 heart transplant recipients, almost 40% had GI complications, of whom 86.3% were treated with GI-protective comedication. 15 These GI complications ranged from mild to moderate complications like diarrhea (58.6%), dyspepsia (24.3%), abdominal pain (27.1%), vomiting (20%) or nausea (22.9%), to more severe, life-threatening diseases such as colon perforation (4.3%) or bleeding (7.1%). 15 Therefore, PPIs have emerged as the most effective class of drugs for the treatment of gastroesophageal reflux disease, as well as several other acid-related disorders.…”

“…15 These GI complications ranged from mild to moderate complications like diarrhea (58.6%), dyspepsia (24.3%), abdominal pain (27.1%), vomiting (20%) or nausea (22.9%), to more severe, life-threatening diseases such as colon perforation (4.3%) or bleeding (7.1%). 15 Therefore, PPIs have emerged as the most effective class of drugs for the treatment of gastroesophageal reflux disease, as well as several other acid-related disorders. 16 All PPIs inhibit gastric acid secretion through binding with H ϩ /K ϩ -adenosine triphosphatase in gastric parietal cells and thereby they can modify the intragastric release of other drugs by elevating the pH value.…”